drug
istradefylline
Marketedupdated 4mo agoby Kyowa Hakko USA Inc
Approvedcommunity read0 votes
indications
investigational
NSCLCParkinson's Disease
all catalysts(0)
nothing on the calendar yet
Trials studying istradefylline
- —Effect of Istradefylline Treatment on Behavioral Measures of Apathy in Parkinson's Disease.
- phase2Istradefylline for Parkinson Disease With Cognitive Impairment
- phase4Istradefylline Effect Protocol on Parkinson's Disease Tremor
- phase3An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001
- phase1Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline
- phase1A Study to Evaluate Abuse Potential of Istradefylline
- phase3A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
- phase3A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 5, 2027
~1.0 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Jan 28, 2028formulationUS 77279931.4y
- Jan 28, 2028formulationUS 77279931.4y
- Sep 5, 2027formulationUS 83182011.0y
- Sep 5, 2027formulationUS 83182011.0y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 7m ago
Found something off?
comments(0)
5-min edit window · permanent after that